Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$17.02 USD
-0.16 (-0.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $17.00 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CNTA 17.02 -0.16(-0.93%)
Will CNTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTA
Centessa Pharmaceuticals (CNTA) Maintains Buy Rating and $30 PT | CNTA Stock News
Alkermes narcolepsy trial results 'encouraging' for Centessa, says Leerink
Centessa Pharmaceuticals (CNTA) Gains Coverage with a 'Buy' Rating | CNTA Stock News
Truist Initiates Coverage on Centessa (CNTA) with Promising Outlook | CNTA Stock News
Centessa initiated with bullish view at Truist, here's why